In addition to licensing the UI research, ArTara has acquired its own IND approval and Orphan Drug Designation from the FDA. In partnership with Novex Innovations,  ArTara also plans to build a U.S.-based manufacturing facility for TARA-002 and win regulatory approval to market TARA-002 in the U.S.